title: FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.
authors.affiliation: Transplant Institute, University of Pittsburgh, PA 15213.
authors.forename: A W
authors.initials: AW
authors.lastname: Thomson
authors.forename: P B
authors.initials: PB
authors.lastname: Carroll
authors.forename: J
authors.initials: J
authors.lastname: McCauley
authors.forename: J
authors.initials: J
authors.lastname: Woo
authors.forename: K
authors.initials: K
authors.lastname: Abu-Elmagd
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
authors.forename: D H
authors.initials: DH
authors.lastname: Van Thiel
mesh_terms: D000328:Adult; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002761:Cholangitis / Q000188:drug therapy; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004066:Digestive System Diseases / Q000188:drug therapy; D004195:Disease Models, Animal; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D051381:Rats; D013552:Swine; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016572:Cyclosporine; D016559:Tacrolimus